Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SINTX Technologies, Inc. filings document an advanced ceramics and biomaterials issuer focused on silicon nitride medical technologies, including formal disclosures on operating results, regulatory communications, capital formation, and governance. Recent Form 8-K reports cover quarterly financial results and Regulation FD disclosures tied to FDA 510(k) activity for silicon nitride foot and ankle medical devices.
The company’s SEC record also includes an at-the-market common stock offering agreement, officer appointment and executive compensation disclosures, and a definitive proxy statement for annual meeting voting. These filings describe board and stockholder matters, material agreements, common stock issuance mechanics, and formal disclosure topics connected to SINTX’s medical-device commercialization and biomaterials platform.
Director Mark Lewis Anderson of Sintx Technologies has reported a significant insider purchase of company shares. On June 18, 2025, Anderson acquired 10,000 shares of Common Stock at a price of $3.30 per share, representing a total investment of $33,000.
Following this transaction, Anderson's direct ownership increased to 15,000 shares of Sintx Technologies common stock. The purchase was executed as a standard market transaction and was reported through Form 4 filed with the SEC on June 28, 2025.
This insider buying activity by a board member could be viewed as a positive signal about the company's prospects, as directors often purchase shares when they believe the stock is undervalued or expect positive developments. The transaction was authorized through power of attorney by Kevin Ontiveros.